NCT04842032View on ClinicalTrials.gov

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 18, 2023

Study Completion Date

December 18, 2023

Conditions

X-linked Hypophosphatemia (XLH)

Interventions

DRUG

KRN23

KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL

Trial Locations (5)

Unknown

Peking Union Medical College Hospital, Beijing

Guangzhou Women and Children Medical Center, Guangzhou

Shanghai 6th Hospital, Shanghai

Shanghai Xinhua Hopsital, Shanghai

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04842032 - Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH | Biotech Hunter | Biotech Hunter